1-t-Butyl-2-methoxynaphthalin | 64807-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-t-Butyl-2-methoxynaphthalin
• 英文别名: 2-Methoxy-1-tert.-butyl-naphthalin；1-tert.-Butyl-2-methoxy-naphthalin；1-Tert-butyl-2-methoxynaphthalene
• CAS: 64807-64-3
• 化学式: C₁₅H₁₈O
• 分子量: 214.307
• InChiKey: GTSFKWGWFCHIPU-UHFFFAOYSA-N

物化性质

• 熔点：
  35 °C
• 沸点：
  328.5±21.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-t-Butyl-2-methoxynaphthalin 、 乙硫醇钠 以21%的产率得到
  参考文献：
  名称：

  CARNDUFF J.; BRADY P. A., J. CHEM. RES. SYNOP., 1977, NO

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-1-萘酸甲酯 、 甲基碘化镁 、 碘甲烷 生成 1-t-Butyl-2-methoxynaphthalin
  参考文献：
  名称：

  CARNDUFF J.; BRADY P. A., J. CHEM. RES. SYNOP., 1977, NO

  摘要：

  DOI：

文献信息

• CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20180015087A1

  公开（公告）日：2018-01-18

  Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

  提供了与谷氨酰脑结合化合物和具有调节活性对抗G12C突变KRAS、HRAS或NRAS G12C蛋白的化合物的共轭物。还提供了与制备和使用这种共轭物相关的方法，包括含有这种共轭物的药物组合物以及调节G12C突变KRAS、HRAS或NRAS G12C蛋白活性的方法，用于治疗癌症等疾病。
• AN ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AGONIST
  申请人：Farmar Licensing Co., Ltd.

  公开号：US20190194142A1

  公开（公告）日：2019-06-27

  The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPKα, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.

  本发明公开了一种化合物(I)的公式，该化合物作为腺苷单磷酸激活蛋白激酶的激动剂，诱导AMPKα的磷酸化和激活，从而进一步调节下游信号通路，抑制肝癌细胞和乳腺癌细胞的生长和增殖，并诱导脂肪细胞凋亡。因此，本发明提供的化合物可用于癌症的治疗和制备药物组合物，以及由AMPK介导的脂质代谢相关疾病或综合征。
• PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE
  申请人：Wainer Irving W.

  公开号：US20100168245A1

  公开（公告）日：2010-07-01

  This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.

  本公开涉及发现(R,R)-和(R,S)-芬特罗类似物，它们在结合β2-肾上腺素能受体方面具有高度有效性。提供了这些类似物的示例化学结构。还提供了包括披露的(R,R)-芬特罗和芬特罗类似物的制药组合物，以及使用这些化合物和组合物治疗心脏疾病（如充血性心力衰竭）和肺部疾病（如哮喘或慢性阻塞性肺疾病）的方法。
• INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20150239900A1

  公开（公告）日：2015-08-27

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E的定义如本文所述。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。
• COMBINATION THERAPIES FOR TREATMENT OF CANCER
  申请人：Araxes Pharma LLC

  公开号：US20160166571A1

  公开（公告）日：2016-06-16

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供了用于治疗与KRAS基因突变相关的癌症的联合治疗方案。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。